Menu Search
Equities

Twist Bioscience Corp

0ME:MUN

Twist Bioscience Corp

Actions
  • Price (EUR)42.00
  • Today's Change0.14 / 0.33%
  • Shares traded80.00
  • 1 Year change+165.65%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.

  • Revenue in USD (TTM)295.21m
  • Net income in USD-220.31m
  • Incorporated2013
  • Employees919.00
  • Location
    Twist Bioscience Corp681 Gateway Blvd.SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (408) 410-0105
  • Fax+1 (302) 531-3150
  • Websitehttps://www.twistbioscience.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.